delivering innovation
to the patient

Specialist in the development of innovative materials for the biomedical field

Highly qualified team with experience in technology transfer

66% of doctors in the team

Scientific based technology developers

OWNED TECHNOLOGY 3 patent families


Self healing
dynamic hydrogels


Single chain polymer nanoparticles for drug delivery


Highly hydrophilic coating for the reduction of wear

With strategic collaborations

that help us in the development of applications in the biomedical sector.

In the core of a strategic network qualified to cover the whole value chain

  • 3 EU Horizon 2020 coordinated projects
  • Member of ETPN Nanomedicine
  • NanoPilot project, led by Cidetec, is one of the initiatives under the umbrella of the Translational Hub in Nanomedicine

Direct contact with industry

to reduce the time to market

  • Readiness to transfer (bio)technology right to the industry
  • GMP Manufacturing Plant:
    According to the pharmacutical regulation for the development of investigational medicinal products.

600 m2 labs dedicated to translational research in nanomedicine

The R&D labs are fully equiped for the characterization of biomaterials

  • Chromatography (HPLC, GPC).
  • Spectroscopy (FTIR, UV, Fluorimetry plate reader).
  • Microscopy (Optical and fluorescence microscopy, FESEM, AFM).
  • Polymer Characterization (TGA, DSC, Rheometer, MALDI-tof, DMA,…).
  • Dynamic light scattering (DLS) and Z Potential, master sizer, Viscosizer.

With unique facilities

165 m2 plant for the manufacturing of medical products under research operating under GMP standards.

Visit our GMP plant

The Pilot Plant can produce small batches of investigational products suitable for pre-clinical and clinical trials

A campaign production has been designed for a flexible production of:

  • Lyophilizates: Up to 1 500 vials / 2 ml
    • Sterile lyophilizates
    • Non-sterile lyophilizates
  • Liquids and aseptic filling
    • Non-sterile liquid formulations
    • Monodoses (500–1000 strips)

Well-defined technological approach


Drug-delivery via inhalation

Lung administration


  • Patient friendly
  • High drug concentrations in affected areas


  • Low efficiency of administered dose
  • Limited administration range

Advantages of nanotechnology:

  • better diffusion
  • homogenous distribution of active ingredients

CIDETEC has developed a technology based on polymer nanoparticles that are obtained from natural polymers of very high biocompatibility.

Because of their small size, under 50 nm, they have a great diffusion capacity, being able to reach the alveoli homogeneously.

This technology allows obtaining particles of low polydispersity in an easily scalable process that takes place in water and is therefore easily adaptable to the requirements of good manufacturing.


Drug-delivery via skin

Natural active principles


  • Highly effective for the regeneration of skin properties


  • not very stable
  • poor penetration
  • Do not respond to the needs of the skin

The encapsulation systems developed to improve their performance do not respond to the needs of the skin and do not increase the absorption of the active ingredients.

CIDETEC in collaboration with the Laboratory of Chemistry of Organic Polymers of the University of Bordeaux (France) has developed a new system of intelligent nanocapsules.

Encapsulation extends the activity of active substances by 30% and responds to the needs of the skin releasing the active principles where they are most needed.

The systems allow an efficiency of almost 100% encapsulation. Due to their nanometric size they penetrate the skin better and completely degrade once they release the active principle, avoiding possible side effects from the use of nanoparticles.


Coatings for prostheses

Polyethylene joint prostheses


  • fatigue resistance
  • Standard material for manufacturers


  • wear resulting in osteolysis by detachment
  • High failure rate at 10 years

Mimicking the surface of natural joints, CIDETEC has developed a technology that maintains the surface of the friction torque of prostheses permanently lubricated and hydrated.

The coating is highly biocompatible and does not alter the synovial fluid and its natural lubricants and also avoids the non-specific adsorption of proteins.

The coatings have been tested on a test bench for five million cycles, reducing the polyethylene wear rate by up to 80% over non-coated material.


GMP Manufacturing

SMEs in the pharmaceutical sector


  • Driving force of innovation
  • Potential of nanotechnologies


  • Highly regulated sector
  • Importance of preclinical and clinical validation

Launching a pharmaceutical product onto the market can cost millions of euros over a period of 15 years.

CIDETEC has a multidisciplinary team who are experts in the transfer of technology in the field of nanomedicine and biomaterials from the laboratory scale to the first clinical batches.

The centre has a pilot plant that operates according to GMP standards for the manufacture of small batches of research drugs aimed at initial clinical phases.

In this way, CIDETEC helps companies put their products on the market, faster and at a lower cost.


Dr. Iraida Loinaz


Andrea Haiek

Head of GMP Unit

Dr. Damien Dupin